- Human Biospecimens
- Biospecimen Contributors
iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online marketplace for human biospecimens, today announced that it will be included in the Russell Microcap® Index, effective after the U.S. market opens on September 20, 2021, as part of the 2021 Russell indexes reconstitution.
iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online marketplace for human biospecimens, today announced that Christopher Ianelli, MD, PhD, CEO and President of iSpecimen, will participate in the H.C. Wainwright 23rd Annual Global Investment Conference to be held virtually on September 13-15, 2021.
On Monday, August 23rd, iSpecimen Founder and Chief Executive Officer to discuss company’s recent IPO, mission and future progress
iSpecimen Inc. (Nasdaq: ISPC), an online marketplace for human biospecimens (“iSpecimen” or the “Company”), today announced it has grown its cancer-related supplier network despite lockdowns, slowdowns, and sustained concern around the COVID-19 pandemic.
iSpecimen Inc. (Nasdaq: ISPC), an online marketplace for human biospecimens announced that an interview with its CEO and President, Dr. Christopher Ianelli, will air on The RedChip Money Report® on Bloomberg TV, at 7 p.m. Eastern Time (ET) on August 14, 2021. Read more to view interview.
-Delivered Revenue Growth of 93% Year-Over-Year-
-Successfully Completed IPO Raising Total Gross Proceeds of $20.7 Million-
iSpecimen Inc, an online marketplace for human biospecimens, reported its financial results for the three-month period ended June 30, 2021.
iSpecimen Inc. (Nasdaq: ISPC) an online marketplace for human biospecimens announced that it has enhanced its custom biofluids collection service to offer life sciences organizations faster delivery of urgently needed research samples.
iSpecimen Inc. (Nasdaq: ISPC), an online marketplace for human biospecimens, today announced that it will report its financial results for the second quarter ended June 30, 2021, before the market open on Tuesday, August 10, 2021.
iSpecimen Inc. (Nasdaq: ISPC) an online marketplace for human biospecimens, today announced the closing of the issuance of an additional 337,500 shares of its common stock pursuant to the full exercise of the underwriters' over-allotment option in connection with the Company's initial public offering (the "IPO"). The additional shares were sold at the initial offering price of $8.00 per share, resulting in additional gross proceeds of $2,700,000 and bringing the total gross proceeds of the IPO to $20,700,000.
iSpecimen Inc. (Nasdaq: ISPC), an online marketplace for human biospecimens, today announced the closing of its previously announced initial public offering of 2,250,000 shares of its common stock at a price of $8.00 per share, for gross proceeds of $18,000,000 before deducting underwriting discounts, commissions and offering expenses. The shares of common stock began trading on the Nasdaq Capital Market under the ticker symbol "ISPC" on June 17, 2021.
iSpecimen, an online marketplace for human biospecimens, today announced the pricing of its initial public offering of 2,250,000 shares of its common stock at a price of $8.00 per share, for gross proceeds of $18,000,000 before deducting underwriting discounts, commissions and offering expenses. In addition, iSpecimen has granted the underwriters a 45-day option to purchase up to an additional 337,500 shares of common stock solely to cover over-allotment.
Procurement of the materials needed for research often introduces delay in the development of new treatments, vaccines, and diagnostics because of the many inefficiencies in the buying process and the many stakeholders who need to be involved. The holy grail for procurement teams and researchers alike would be solutions that are as efficient as the mouse click that puts an Amazon purchase on your doorstep in 24 hours.
Long before a clinician administers a drug or runs a new test, there is the arduous R&D cycle. Unfortunately, it’s rarely as streamlined as the one that just delivered COVID-19 vaccines in record-shattering time.
As healthcare digitizes everything from insurance claims to clinical decisions, some functions remain frustratingly analog, old school, and inefficient. One such function is the distribution of human biospecimens necessary for medical research.
LEXINGTON, MA, February 3rd, 2021– iSpecimen today announced it has expanded its cellular biospecimen offerings by introducing new cryopreserved stem and immune cell products for life science research and preclinical drug development. The new products are intended to support the growth of regenerative medicine by giving researchers broader access to the materials they need to develop new therapies.
The need for sharing information across the medical research landscape was never starker than during the early days of the COVID-19 pandemic. A spirit of urgency and collaboration broke down traditional informational barriers as industry and academia organized like never before in modern history to develop a vaccine in just nine months.
We wish to express our deepest condolences to the family of Andrew I. Brooks, Ph.D., one of our corporate advisors and our dear friend of many years...
Every medical breakthrough starts with the study of afflicted patients, often through their blood, tumor tissue, or other biological material. Thus, it’s critical for the advancement of life science research that scientists can easily procure the human biospecimens they need in the right form and quantity from specific patient populations – both those with the medical condition being studied and healthy normal controls. Medical progress depends on it.
LEXINGTON, MA, Dec. 17, 2020 –Through the iSpecimen Marketplace™, medical researchers can now access a new daily source of biospecimens from patients who have recently taken COVID-19 tests and consented to release their de-identified data. These biospecimens, including nasopharyngeal swabs, come with de-identified data from patients’ medical records that is important to researchers.
LEXINGTON, MA, Sept. 30, 2020 – iSpecimen, the marketplace for human biospecimens for medical research, today named corporate finance veteran Tracy Wilson Curley as its Chief Financial Officer.
Some good news: non-COVID medical research, including clinical trials, has partially resumed after widespread suspensions, delays and slowdowns during the outbreak. Fifty-seven percent (57%) of the U.S. trials disrupted at the first peak of the pandemic in April had recovered by July, meaning they were either currently active or completed.
For precision medicine to realize its potential, research must become ultraefficient. We have the computing power today to quickly discover new disease biomarkers and insights, but we still need enormous volumes of patient population data to analyze. And we need that new data faster.
LEXINGTON, MA, May 20, 2020 – iSpecimen today announced a new initiative in the battle against COVID-19 and other diseases – mobile phlebotomy support that will bring convenient, at-home sample collection to patients and donors interested in advancing research who would otherwise have limited ability to participate.
LEXINGTON, MA, May 12, 2020 – iSpecimen today announced it will supply the U.S. Centers for Disease Control and Prevention (CDC) with serum samples from subjects who have previously tested positive for SARS-CoV-2, the virus that causes COVID-19.
LEXINGTON, MA, April 16, 2020 – iSpecimen today announced it is deeply engaged in the battle against COVID-19, supporting researchers who are working on urgently needed vaccines, tests and treatments for the deadly viral disease. The novel coronavirus is one of the highest priorities of medicine today, and iSpecimen’s immediate response is integral to the company’s long-term mission. For eight years, the company has advanced medical progress by connecting researchers with the human biospecimens and data they need to perform their work.
The outbreak of the COVID-19 virus poses many new challenges for all of us. We at iSpecimen are continuously monitoring the outbreak and taking both actions and precautions necessary to ensure business continuity while maintaining the safety of our employees and their families.
Every day counts when it comes to saving lives and generating revenue, especially when you’re trying to bring a drug, treatment, or diagnostic tool to market. Unfortunately, these processes often take a lot longer and cost a lot more than initially expected.
LEXINGTON, Mass., Sept. 24, 2019 — Devoted to supporting life science researchers who urgently pursue breakthroughs, iSpecimen today announced it has partnered with new providers of diseased and healthy hematologic tissue to offer one of the industry’s largest, most integrated networks of donors and collection sites available while addressing proliferating demand for hematopoietic stem and immune cell products.
LEXINGTON, July 17, 2019— iSpecimen, a leading provider of biospecimens for life science research, today announced the expansion of its leadership team with the appointment of Wayne Vaz as vice president of growth and corporate development.
No one likes waste. We close our windows when the AC is on. We invest our savings. We recycle our grocery packaging so the material can be used once again. How, then, can we in the medical community discard untold volumes of human blood, urine, and other biofluid specimens that flow through U.S. clinical labs every year—specimens that researchers desperately need?
LEXINGTON, MA, May 8 2019—Life sciences data and informatics expert Dave John has joined iSpecimen as vice president of product management.
During his service at the Brigham and Women’s Hospital in Boston, Dr. Christopher Ianelli noticed a software solution that orchestrated the distribution of leftover specimens to researchers developed within the clinical laboratory of the hospital. Acknowledging that these “clinical remnant” specimens held tremendous value for medical research, he quickly realized the power of this solution to reduce waste and accelerate research by connecting bench researchers to a steady supply of remnant clinical samples. This outstanding discovery made Dr. Ianelli shift his career to technology-based solutions, from the clinical side of medicine, and launch iSepcimen—a human biospecimen marketplace technology company.
On Wednesday, April 24th, 2019, iSpecimen will host the webinar, "From Chaos to Control - Transforming Biospecimen Procurement." Register now.
SAN FRANCISCO, CA, March 12, 2019 – iSpecimen Founder and CEO Christopher Ianelli, MD, PhD, will appear on a panel of senior executives exploring hot technologies and topics in molecular medicine tomorrow at Molecular Med TRI-CON here in San Francisco.
On March 13th, iSpecimen Founder and CEO Christopher Ianelli, MD, PhD, will appear on a panel of senior executives exploring hot technologies and topics in molecular medicine at Molecular Med TRI-CON in San Francisco.
LEXINGTON, MA, March 4, 2019 – iSpecimen today announced that researchers and suppliers are joining the iSpecimen Marketplace at a robust rate, with both populations more than doubling yearly since the Marketplace was introduced in mid-2017.
Imagine a library that purchases books but is unwilling to lend them to more than a few select people, a dating site with no way to see the available singles, or eBay with no button for obtaining what you see. That’s similar to what what’s happening in biomedical research today and, specifically, in the biospecimen world. An estimated 500 million human biospecimens – biofluids, tissue and cells – reside in U.S. biorepositories. That’s more than one specimen for every citizen in the U.S., theoretically ready to be studied. Researchers, however, are having a hard time getting their hands on these specimens for their work on new treatments, diagnostics, and cures.
LEXINGTON, MA, Jan. 23, 2019 – Addressing the needs of leading life science and cell therapy researchers, iSpecimen today significantly enhanced its human biospecimen offerings with the addition of fresh primary hematopoietic cells, affirming the iSpecimen Marketplace as one of the most complete and comprehensive sources of human biospecimens for research.
LEXINGTON, MA, Oct. 30, 2018 – iSpecimen today significantly upgraded its online exchange for biospecimens, making it easier for healthcare organizations to offer their valuable biospecimen collections to researchers around the world, and for researchers to obtain the specimens they desperately need.
An estimated 500 million human biospecimens—biofluids, tissue and cells—reside in U.S. biorepositories. That’s more than one specimen for every citizen, ready for study. Meanwhile, four out of five researchers tell the National Cancer Institute they’ve had to limit the scope of their work because of the difficulty of procuring high-quality specimens.
LEXINGTON, MA, August 27, 2018 — Veteran healthcare informatics expert Benjamin Bielak has joined iSpecimen as its first Chief Information Officer to lead further development of the iSpecimen Marketplace, an online platform that connects biomedical researchers with the biospecimens they need for their work developing new diagnostics, treatments and cures.
Mandates to keep biospecimens in house are among the factors
inhibiting better specimen sharing today.
LEXINGTON, MA., May 22, 2018 - A majority of global biobanks – collectors of human fluids, cells and tissue for biomedical research – are underutilizing their specimens while struggling with financial pressures that threaten their long-term viability, suggests a new review of biobanks and biorepositories conducted by iSpecimen.
LEXINGTON, MA, April 25, 2018 – iSpecimen today announced it has established a panel of respected partners and industry experts to counsel the company in its mission of supplying biomedical researchers with the specimens they need from the patients who have them.
Lexington, MA - April 12, 2018 - Siemens Healthineers and iSpecimen today announced they will aid laboratories in generating new sources of revenue through the integration of Siemens Healthineers’ laboratory automation systems with iSpecimen’s biospecimen marketplace. Participating labs can use the CentraLink Data Management System and Aptio® Automation to automate retrieval of samples requested by researchers via the iSpecimen Marketplace.
ZURICH, Switzerland, March 13, 2018 – iSpecimen Director of Marketing Jeff Goldman and partner Science Exchange will co-present today, March 13, at the ProcureCon Europe Pharma Conference in Switzerland. The presentation will demonstrate how iSpecimen’s digital marketplace addresses challenges along the research supply chain, and share industry perspectives on biobanking and procurement.
San Francisco, Calif., Feb. 12, 2018 – iSpecimen Founder and CEO Christopher Ianelli, MD, PhD, will co-present on the emerging technologies and industry perspectives in molecular medicine on Wednesday, Feb. 14 at Molecular Med TRICON in San Francisco.
December 18, 2017 - Becker's Hospital Review - As the new quest for individualized cures progresses and patients increasingly constitute an “N of 1,” it’s becoming apparent that precision research will be essential to achieving the promise of precision medicine.
Lexington, MA, Dec. 5, 2017 – iSpecimen today announced the iSpecimen Data Connector Program, an initiative that enables health-care organizations to seamlessly connect their sample and data management systems to the iSpecimen Marketplace, making it easier than ever to offer their biospecimens to researchers.
LAUSANNE, Switzerland, and LEXINGTON, MA, Dec. 5, 2017 – Genohm and iSpecimen today jointly announced that Genohm has established a partnership with iSpecimen to enable users of the SLIMS laboratory information management system to seamlessly connect to the iSpecimen Marketplace.
The combined solution will allow Genohm customers to easily make their inventories of biospecimens and associated data available to researchers around the world through the marketplace, and then accept, fulfill and track associated orders for samples. These new capabilities enable Genohm customers to increase revenue as well as the utilization rates of their banked specimens.
Lexington, MA and Palo Alto, CA – Oct. 24, 2017 – iSpecimen and Science Exchange today announced a marketplace technology integration that will allow Science Exchange users to directly search for biospecimens available in the iSpecimen Marketplace via a single user interface.
Lexington, MA – October 23, 2017 – iSpecimen® today announced the expansion of the iSpecimen Marketplace – an online specimen matching platform launched in June of this year that instantly connects life science researchers who need human biospecimens with the healthcare organizations that have them. Hundreds of biotech, pharmaceutical, and academic institutions have signed on as marketplace users, collectively conducting thousands of searches across millions of patients and samples available for research. Initially launched providing access to one million banked samples, the iSpecimen Marketplace now also provides access to 25 million clinical remnants annually.
October 2, 2017 - Outsourcing Pharma - To simplify the human biospecimens procurement process, the online marketplace for outsourced scientific services, Scientist.com, has teamed up with iSpecimen.
San Diego, CA and Lexington, MA – October 2, 2017 – Scientist.com, the life science industry’s leading online marketplace for outsourced scientific services, and iSpecimen, a leading supplier of human biospecimens used for scientific research, today announced that they will simplify access to highly annotated human samples of all types. Researchers in the pharmaceutical and biotechnology industries can now access millions of data-rich human biospecimens and acquire them online under a single pre-established legal agreement.
August 21, 2017 - The Boston Globe - More than 50 hospital systems and commercial laboratory networks in Massachusetts and elsewhere have signed deals with iSpecimen, giving researchers access to millions of tissue and fluid specimens. That could greatly expand the power of labs like SQZ to conduct cutting-edge research.
June 15, 2017 - HIT Consultant - iSpecimen, a Lexington, MA-based startup has launched the iSpecimen Marketplace, an online, data-rich platform that connects life science researchers who need human biospecimens to the healthcare organizations that have them. Using a powerful, multi-faceted search platform, the marketplace enables medical researchers to intuitively search millions of available human biospecimens and solves one of the research industry’s biggest challenges – how to compliantly obtain quality biospecimens in a cost-effective manner. Through the marketplace, researchers gain instant access to iSpecimen’s growing, federated network of healthcare providers and biobanks, giving network participants (specimen providers) the opportunity to more broadly contribute to medical research as well as their bottom line.
June 14, 2017 - ClinicalOMICS - Human biospecimen marketplace iSpecimen, has launched an online platform called iSpecimen Marketplace with the intent of quickly connecting life sciences researchers in need of specific biosamples with the biobanks and clinical laboratories that have them. The searchable platform, which carries broad similarities to other consumer marketplaces like travel-oriented sites Travelocity and Kayak, provides a search platform for researchers to enter the type of sample they seek, then narrow it down to their specific parameters in order to identify the most relevant biospecimens available from the suppliers in the network.
June 13, 2017 - BIO IT World - iSpecimen launched its marketplace today, an online shopping platform to connect life science researchers to healthcare organizations with human biospecimens. The platform is designed to maximize user experience. Researchers start by requesting tissue, biological fluids, or viable cells. From there, the platform pulls up a results list that is very similar to results in Amazon or Kayak. On the left, a panel of check boxes and sliders help researchers narrow their results by specimen details, molecular characterization, patient demographics, histology, and more.
June 13, 2017 - Boston Business Journal - A Lexington company has launched a new online marketplace that connects medical researchers with suppliers of human tissue and other biospecimens — a kind of Amazon.com for the life sciences industry. The privately-held company, iSpecimen, unveiled the marketplace on Tuesday. The platform aims to solve a problem that remains all too common among scientists: canvassing hospitals, labs and other healthcare organizations to find specific, high-quality samples of human material needed to conduct research. Such searches can be time-consuming and, if they fail to identify adequate biospecimens, force researchers to change or curtail the scope of their projects.
Lexington, MA – June 13, 2017 – iSpecimen® today launched the iSpecimen Marketplace – an online, data-rich platform that connects life science researchers who need human biospecimens to the healthcare organizations that have them. Using a powerful, multi-faceted search platform, the marketplace enables medical researchers to intuitively search millions of available human biospecimens and solves one of the research industry’s biggest challenges – how to compliantly obtain quality biospecimens in a cost-effective manner. Through the marketplace, researchers gain instant access to iSpecimen’s growing, federated network of healthcare providers and biobanks, giving network participants (specimen providers) the opportunity to more broadly contribute to medical research as well as their bottom line.
March 17, 2017 - 360Dx - Sample collection firm iSpecimen is developing a cloud-based system for streamlining procurement of patient samples. The system, which the company plans to launch in May, will allow researchers to place online requests for specific sample types that iSpecimen will then work to fill via its various clinical partners. Comparing it to travel websites like Kayak.com, Christopher Ianelli, iSpecimen's founder and CEO, said the tool will allow users to "go to our website and enter in exactly what they need, and then we'll search across our network and tell them when we find what they are looking for." According to the company, its network of sample providers currently consists of more than 250 hospitals labs, 1,000 clinics and medical practices, 12 biorepositories, 10 commercial labs, six clinical trial organizations, and one large blood center.
Lexington, MA – March 22, 2017 – iSpecimen®, the marketplace for human biospecimen collections, today announced that Doctors Pathology Service (DPS), a full-service anatomic pathology reference lab serving the mid-Atlantic region of the United States, has joined a program offered by iSpecimen and the Delaware Health Information Network (DHIN) to make human biospecimens and associated data available to medical researchers.
February 27, 2017 - Diagnostic Testing & Emerging Technologies - iSpecimen (Lexington, Mass.) can be thought of as a cross between a dating site and an online marketplace for human biospecimens. The company has built a turnkey solution that connects providers, such as hospital systems, commercial labs, and biobanks, to researchers looking to gain access to these specimens and associated data from electronic medical records and other sources. It’s a win-win situation, with providers having a new market for both soon-to-be discarded and banked specimens, researchers more efficiently accessing needed specimens and rich clinical data, and patients getting a chance to make a contribution to research.
February 24, 2017 - BIO-IT World - We are, in many ways, spoiled for choice. In nearly everything we buy we expect to be able to shop consolidated market places, with the wealth of our options organized before us. We want to be able to search and filter our own results. And we really like one-click shopping. The same is true for human samples.
Lexington, MA – February 16, 2017 – iSpecimen®, the marketplace for human biospecimen collections, today announced that its founder and chief executive officer, Christopher Ianelli, MD, PhD, will join a panel of medical innovators next week in presenting emerging technologies for molecular medicine. This keynote panel will take place on Wednesday, February 22 as part of the Cambridge HealthTech Institute’s Molecular Med Tri-Con event in San Francisco.
January 22, 2017 - Monday Morning - Up first is Dr. Christopher Ianelli, founder and CEO of iSpecimen. His company is a supplier of human biospecimens to the life science industry, including pharmaceutical, diagnostic, and academic researchers. “In 2016, ‘precision medicine’ reigned supreme as the catch phrase of the year,” he writes, according to STAT. Dr. Ianelli then goes on to predict, “‘Precision research,’ or the ever-more targeted research necessary to make good on the promise of precision medicine, will propel forward in 2017. Refined research questions requiring the interrogation of highly specific biospecimens and associated data sets will form the backbone of this precision research wave.”
January 3, 2017 - STAT News - Sharper focus on precision research: "Precision research, or the ever-more targeted research necessary to make good on the promise of precision medicine, will propel forward in 2017. With nationwide health care initiatives getting attention, like the National Institutes of Health’s PMI and Joe Biden’s cancer moonshot, scientists are in pursuit of customized therapies for an N of 1. Refined research questions requiring the interrogation of highly specific biospecimens and associated data sets will form the backbone of this precision research wave." — Dr. Christopher Ianelli, founder and CEO of iSpecimen
December 8, 2016 - Lab Manager - iSpecimen, a trusted source of customized human biospecimen collections, today announced that it has made sizeable increases to the number and types of clinical organizations participating in its partner network. As a result, the company can now offer scientists faster access to a more diverse array of human biospecimens for medical research. Initially founded as a provider of remnant clinical biospecimens, iSpecimen can additionally source biospecimens collected specifically for research from its partner network that includes hospitals, commercial labs, clinics and practice groups, biorepositories, blood centers, health information exchanges, and clinical research sites.
December 6, 2016 - Xconomy - Great Lakes Health Connect (GLHC), Michigan’s leading health information exchange (HIE), has announced a partnership with Massachusetts-based iSpecimen to help advance precision medicine research. All GLHC participating providers (129 hospitals and over 4,000 other members) will now have the option to donate their patient-consented biospecimens to scientists doing diagnostic and clinical testing.
Lexington, MA – December 7, 2016 – iSpecimen®, a trusted source of customized human biospecimen collections, today announced that it has made sizeable increases to the number and types of clinical organizations participating in its partner network. As a result, the company can now offer scientists faster access to a more diverse array of human biospecimens for medical research. Initially founded as a provider of remnant clinical biospecimens, iSpecimen can additionally source biospecimens collected specifically for research from its partner network that includes hospitals, commercial labs, clinics and practice groups, biorepositories, blood centers, health information exchanges, and clinical research sites.
November 24, 2016 - Grand Rapids Business Journal - A local health information exchange will provide human bio-specimens and data to a supplier serving the medical research industry under a new partnership. Grand Rapids-based Great Lakes Health Connect, or GLHC, a nonprofit, has agreed to partner with Lexington, Massachusetts-based iSpecimen, a privately held company.
November 18, 2016 - GenomeWeb - Customized human biospecimen collections developer iSpecimen said this week that it has signed an agreement to help New Mexico-based commercial lab TriCore Reference Laboratories make patient biospecimens and associated data available for research. iSpecimen will use its cloud-based technology to analyze data generated by TriCore to match researchers with annotated, de-identified samples for their studies.
November 16, 2016 - Lab Manager - iSpecimen®, a trusted source of customized human biospecimen collections, and TriCore Reference Laboratories (TriCore), New Mexico's largest commercial reference lab, today (Nov. 14) announced an agreement through which iSpecimen will serve as a TriCore channel partner for making patient biospecimens and associated data available for research. iSpecimen's cloud-based technology will be used to tap into the flow of patients, specimens, and data running through the TriCore organization, matching researchers with a variety of annotated, de-identified samples to fuel their studies.
November 14, 2016 - Albuquerque Journal - New Mexico-based TriCore Reference Laboratories on Monday said it has inked an agreement with iSpecimen, a Boston company that connects medical researchers with appropriate specimens from laboratories and hospitals. “TriCore has been a long-time supporter of the advancement of biomedical research,” said Eric Carbonneau, director of the core lab operations & research institute at TriCore. “The new agreement with iSpecimen will allow us to expand our reach across the scientific community."
November 11, 2016 - Health Data Management - Patients benefiting from the Great Lakes Health Connect health information exchange in Michigan now will be able consent to donate biospecimens to researchers. The HIE has contracted with vendor iSpecimen, enabling researchers to use their electronic health record system to view and select specific samples in real-time, as well as get patients’ medical histories upon consent. Great Lakes Health Connect participants manage more than 90 percent of hospital beds in the state and have more than 7 million individual patient records.
November 9, 2016 - Clinical Innovation & Technology - iSpecimen, a supplier of human biospecimens, and Great Lakes Health Connect (GLHC), the leading health information exchange (HIE) in Michigan, have teamed to improve the data network of biospecimens available for research purposes. With 129 hospitals and 4,000 primary, specialty and allied care organizations, GLHC is in charge of over 90 percent of hospital beds in Michigan with more than seven million patient records. By consolidating the data on human biospecimens, iSpecimen is able to sort large amounts of data form electronic medical records and make them easily accessible to researchers looking for a specific set of patients.
Lexington, Mass. & Albuquerque, N.M., November 14, 2016 – iSpecimen®, a trusted source of customized human biospecimen collections, and TriCore Reference Laboratories (TriCore), New Mexico’s largest commercial reference lab, today announced an agreement through which iSpecimen will serve as a TriCore channel partner for making patient biospecimens and associated data available for research. iSpecimen’s cloud-based technology will be used to tap into the flow of patients, specimens, and data running through the TriCore organization, matching researchers with a variety of annotated, de-identified samples to fuel their studies.
November 7, 2016 - MedCity News - In mid-October, the National Institutes of Health announced that its Precision Medicine Initiative (PMI) Cohort Program has expanded to include four additional regional medical center groups – the California Precision Medicine Consortium, Geisinger Health System, the New England Precision Medicine Consortium, and the Trans-American Consortium for the Health Care Systems Research Network. These groups, which collectively consist of nearly 20 distinct institutions, will work in concert with the other existing healthcare provider organizations (HPOs) taking part in the PMI to recruit the one million participants necessary to complete the PMI cohort. More than ever, medical philanthropy – the willingness of patients to give of themselves for the advancement of healthcare research – will be critical to achieving this as well as other precision medicine endeavors.
November 4, 2016 - Lab Manager - iSpecimen, a trusted source of customized human biospecimen collections, today (Nov. 3) announced an agreement with Great Lakes Health Connect (GLHC), Michigan’s leading health information exchange (HIE). This agreement will drive medical innovation by making human biospecimens and associated data from within the GLHC network available to research programs. With 129 hospital participants as well as 4,000 primary, specialty, and allied care organization members, GLHC participants manage more than 90 percent of the hospital beds in the state and over seven million individual patient records.
Lexington, MA – November 3, 2016 – iSpecimen®, a trusted source of customized human biospecimen collections, today announced an agreement with Great Lakes Health Connect (GLHC), Michigan’s leading health information exchange (HIE). This agreement will drive medical innovation by making human biospecimens and associated data from within the GLHC network available to research programs. With 129 hospital participants as well as 4,000 primary, specialty, and allied care organization members, GLHC participants manage more than 90% of the hospital beds in the state and over seven million individual patient records.
October 21, 2016 - PharmaLive - Competition amongst biotech and pharmaceutical companies is certainly nothing new, with firms working arduously to maintain solid pipelines, win disease state areas, and attract and retain top talent. An industry marked by mass consolidation of established organizations on one end, and seemingly ongoing entry of “next-generation” start-ups on the other, it is no surprise that differentiation and market share are top-of-mind for biopharma executives. Yet, far before there are new therapies to set a firm apart, or enough sales to garner Wall Street’s attention, there is a far more fundamental need that competitiveness will ultimately hinge on – and that is the need for high-quality, diversified, annotated human biospecimens. Without access to a ready supply of these specimens, particularly as precision medicine continues to reign supreme, today’s biopharma companies will falter, quite literally, getting off the bench.
September 12, 2016 - Mayo Clinic Individualized Medicine Blog - iSpecimen®, a privately held biomedical company, has announced a new collaboration with Mayo Clinic Center for Individualized Medicine to make serum from cancer patients more readily available to scientists. Bringing together patient samples, scientists and biomedical business is an important step toward advancing research into personalized treatments for cancer, Alzheimer’s and many other diseases. “Breakthrough discoveries would not be possible without the human samples investigators use in their studies,” says Stephen Thibodeau, Ph.D., the David F. and Margaret T. Grohne Director, Biorepositories Program, Mayo Clinic Center for Individualized Medicine.”
September 12, 2016 - HIT Consultant - Mayo Clinic Center for Individualized Medicine has selected iSpecimen to serve as the exclusive channel partner for the Mayo Clinic Cancer/Normal Serum Biobank, connecting biomedical researchers with the samples and associated data for their studies. The Cancer/Normal Serum Biobank has approximately 130,000 frozen vials of serum from about 17,000 unique, consented patients. iSpecimen will manage the serum inventory and associated data through its cloud-based technology solution, matching researchers to the right samples to fuel their studies.
September 12, 2016 - Bioscience Technology - Bioscience Technology chatted with Chris Ianelli, CEO of iSpecimen, to discuss the public attitude toward donating biological samples for clinical research, why participation in research efforts is important, and some roadblocks to sample collection.
September 12, 2016 - GenomeWeb - Biological specimen provider iSpecimen announced today that it has signed an agreement to exclusively manage serum samples and associated data for the Mayo Clinic Center for Individualized Medicine's Cancer Serum Biobank. The biobank holds roughly 130,000 frozen serum samples collected between 1975 and 1990 from about 17,000 unique Mayo Clinic patients covering 85 malignant and benign cancers, as well as normal controls. It also includes patient diagnosis and treatment data.
September 12, 2016 - Becker's Health IT & CIO Review - Mayo Clinic Center for Individualized Medicine in Rochester, Minn., has selected iSpecimen to connect biomedical researchers with the samples and data held in the center's biobank for studies. The Cancer/Normal Serum Biobank holds approximately 130,000 frozen vials of serum from 17,000 consenting patients. The samples were collected between 1975 and 1990.
September 8, 2016 - Lab Manager - Christopher Ianelli, chief executive officer of iSpecimen (Lexington, MA), points out a well-known problem that starts in preclinical research and goes through to clinical trials: a dearth of high-quality, data-rich human biospecimens. He adds, “Particularly with the surge of personalized medicine research, qualified human samples— with very specific specimen- and patient-level criteria— are in tremendous demand.”
Lexington, MA – September 12, 2016 – iSpecimen®, a trusted source of customized human biospecimen collections, today announced that it has entered into an agreement with the Mayo Clinic Center for Individualized Medicine. Under the agreement, iSpecimen will serve as the exclusive channel partner for the Mayo Clinic Cancer/Normal Serum Biobank, connecting biomedical researchers with the samples and associated data for their studies. The Cancer/Normal Serum Biobank, located on Mayo Clinic’s campus in Rochester, Minnesota, includes approximately 130,000 frozen vials of serum from about 17,000 unique, consented patients. The samples were collected between 1975 and 1990 across 85 different malignant and benign conditions.
September 5, 2016 - ADVANCE for Health System Management - More than six years have passed since the Affordable Care Act (ACA) was signed into law and more than seven years since the Health Information Technology for Economic and Clinical Health (HITECH) Act took place. Tremendous strides have been made in the adoption of electronic medical records (EMR), which both laws sought to encourage, but there is still a long way to go for many medical care sites in terms of getting the most out of these heavy investments. One way to leverage EMR implementation, and reap both clinical and financial benefits over and above the intended benefits from better coordination of care, involves using the EMR past the point of care, to help researchers obtain biospecimens and data from patients they want to study. EMRs provide data aggregation that is wildly useful to researchers when it is de-identified and coupled with corresponding patient biospecimens. Let’s take a closer look at how this works.
August 3, 2016 - Dark Daily - Are health information networks alive and well in the United States? This sector of healthcare has been quiet in recent years. However, there is one statewide health information exchange (HIE) that is doing innovative things with clinical laboratory specimens. The Delaware Health Information Network (DHIN) has entered into a novel collaboration with iSpecimen that may help address the medical research community’s growing need for clinical specimens. At the same time, this agreement will also provide a much-needed new revenue stream for participating medical laboratories and hospitals.
July 25, 2016 - Genetic Engineering News - As advances in precision medicine persist, and we collectively get closer to truly treating every patient as an “N of 1”, the challenge of finding the right human biospecimens on which to conduct preclinical research has grown significantly. Research into newer diagnostic tests, spanning an ever-growing range of “omics”, and treatment methods such as the recently approved cancer immunotherapies, require highly specific and highly characterized samples on which to conduct the research. These required characterizations may include specimen parameters that previously were unavailable—such as documented warm/cold ischemic times and specific molecular characterizations—in addition to precise patient parameters—such as specific treatment histories and responses. Finding these specimens has been difficult, at best, but with the advent of electronic medical records, big data technologies, more sophisticated specimen collection processes, increased genomic testing, and of course the overall progression of medicine, researchers have a myriad of new options to help them obtain the specimens they need from the patients they want.
June 26, 2016 - SearchHealth IT - Precision health will be achieved only if people and companies from various sectors work together. That's why President Barack Obama started his precision medicine initiative, in an effort to bring researchers, doctors and patients together and to encourage hospitals and people to share data in order to better understand certain diseases and discover cures. A small company in Massachusetts is working to achieve precision health by using their technology to bring hospitals and researchers together. Researchers have a growing need for patient samples and specimens -- including everything from blood, serum, plasma and tissue -- and providers such as hospital systems, practice groups, commercial labs and blood centers often take and collect specimens from patients. iSpecimen saw an opportunity here.
Lexington, MA - June 2, 2016 - iSpecimen®, a trusted source of customized human biospecimen collections, today announced the appointment of Eric Langlois to the position of Vice President of Sales and Business Development. In this role, Eric will be responsible for driving company sales as the firm offers a broader range of biospecimens to the scientific community, including biofluids, solid tissue, and viable cells, all paired with de-identified patient- and specimen-level data to meet researcher needs.
May 23, 2016 - ADVANCE for Laboratory - We recently spoke with Michael Clare-Salzler, MD, chair of the department of pathology, immunology and laboratory medicine at the University of Florida Health, as well as Amer Abouhamze, MHA, assistant director at the University of Florida Clinical & Translational Science Institute Biorepository, about the evolution of their state-of-the-art biobank. We discussed how data needs and improvements have changed the way the bank operates and what they deem critical for sustainability in meeting researchers' needs in the age of personalized medicine. iSpecimen is one of several distribution channels they use to move their specimens into biomedical research.
April 11, 2016 - Advance for Laboratory - Increasingly, hospital-based and commercial labs are being leveraged as a source of patient biospecimens and associated data for research. But how do patients feel about this? A new study commissioned by iSpecimen, but conducted independently, indicates that Americans are largely supportive of the use of their leftover clinical specimens for research, particularly when they learn that these specimens will otherwise be discarded and that their privacy can be ensured. Based on the study, it appears that Americans view this as a way they can contribute philanthropically to the advancement of medicine.
March 29, 2016 - Healthcare Informatics - Through this program, healthcare information from participating DHIN members is de-identified and matched to corresponding remnant specimens at their provider sites. The specimens and their data are then searchable in real-time using iSpecimen's technology. When matches are made, iSpecimen's technology instructs laboratory personnel at participating provider sites to pick and ship the specimens to iSpecimen's research customers instead of discarding them as they usually do once clinical testing is complete.
December 16, 2015 - PM360 - iSpecimen has created a new paradigm for specimen procurement through which technology easily interfaces with health information systems at hospitals and labs to watch the flow of soon-to-be-discarded specimens and their associated data. When a match to a researcher request is made, specimens are picked, packed and shipped in an automated, HIPAA-compliant, efficient manner to researcher customers.
December 16, 2015 - MedCity News - Patients are getting more engaged in their care processes, which has led to an interesting new trend: We’re now seeing a more philanthropic patient. But not just in terms of donating dollars: Patients are willing to participate more and more in research, as Boston startup iSpecimen has found in an interesting independent analysis of patients participate in medical research. “The driving force behind this is for us to figure out, do patients really want to give something of themselves for healthcare research?” iSpecimen CEO Christopher Ianelli said in a phone interview.
Lexington, MA - December 16, 2015 - A new study commissioned by iSpecimen, a trusted source of customized human biospecimen collections, reveals that Americans want to support medical research and are willing to literally give of themselves. The study found 83% of Americans are willing to allow the use of their remnant clinical specimens in research, meaning once medical testing is completed, any leftover sample could be de-identified and made available to scientists who might need them in the search for new diagnostics or treatments. Close to two-thirds of the study sample were even willing to give an extra tube of blood if asked, for the sole purpose of use in research.
November 10, 2015 - Advance for Laboratory - iSpecimen, a trusted source of customized human biospecimen collections, and the Delaware Health Information Network (DHIN), the nation's first operational statewide health information exchange (HIE), recently announced a novel collaboration to support medical research. The joint program allows hospitals and labs in the DHIN network to easily repurpose remnant clinical specimens - samples that would otherwise be discarded once patient testing is complete - into medical research programs, while reducing their costs to participate in DHIN. The organizations also announced Union Hospital as the first DHIN member to participate in the joint program.
November 5, 2015 - Health IT Outcomes - In a novel collaborative program designed to support medical research, iSpecimen and the Delaware Health Information Network (DHIN), the nation’s first operational statewide health information exchange (HIE), have announced a joint program allowing hospitals and labs in the DHIN network to easily repurpose remnant clinical specimens into medical research programs while reducing their costs to participate in DHIN. Union Hospital will be the program’s initial member.
October 29, 2015 - Health Data Management - The Delaware Health Information Network, a statewide health information exchange that also serves parts of Maryland, is offering a novel new program—the exchange of medical specimens among hospitals and researchers. The idea is to repurpose liquid and solid clinical laboratory specimens, such as tissues, plasma, serum, blood and urine, so that hospitals no longer destroy leftover specimens but make them available—with patient consent—to medical research programs.
October 22, 2015 - Last fall, the Delaware Health Information Network announced a collaboration with the Lexington, Mass.-based biospecimen collection company iSpecimen, with the goal to allow hospitals and labs in the DHIN network to repurpose remnant clinical specimens into medical research programs.
October 22, 2015 - The News Journal - The Delaware Health Information Network, the state's healthcare data exchange network, has partnered with iSpecimen to support medical research.Under the agreement, hospitals and labs in the DHIN network will reuse patients' clinical specimens in medical research organizations. Lexington, Massachusetts-based iSpecimen, which collects medical samples and specimens, will be responsible for shipping and handling the specimens. All specimens and their data are searchable in real-time using iSpecimen's technology.
Lexington, MA and Dover, DE – October 21, 2015 – iSpecimen, a trusted source of customized human biospecimen collections, and the Delaware Health Information Network (DHIN), the nation’s first operational statewide health information exchange (HIE), today announced a novel collaboration to support medical research. The joint program allows hospitals and labs in the DHIN network to easily repurpose remnant clinical specimens – samples that would otherwise be discarded once patient testing is complete – into medical research programs, while reducing their costs to participate in DHIN.
September 10, 2015 - Lab Manager - With the promise of personalized medicine, the drug and diagnostic industries are booming, as are academic medical research programs. Never before have we seen such a proliferation of research questions, magnifying the need for human biospecimens on which to conduct the research. But finding qualified human biospecimens has long been a problem, with researchers often unable to find enough, or the right type, or the right quality to meet their needs.
August 21, 2015 - MedCity News - Boston startup iSpecimen is building a sort of next-gen version of biobanking: It sources these remaining patient samples, and makes them – and the associated data – available to researchers on demand. The company doesn’t work like a typical biobank. It isn’t a repository for excreta. Rather, it’s more of a tech company that sources biological samples remotely from a hospital system or a clinical lab, then arranges for it to be sent to the researcher. And because iSpecimen doesn’t have to store its own samples, it can tout access to more than 10 million patient samples.
January 30, 2015 - Building on President Obama’s announcement in his State of the Union Address, today the Administration is unveiling details about the Precision Medicine Initiative, a bold new research effort to revolutionize how we improve health and treat disease. Launched with a $215 million investment in the President’s 2016 Budget, the Precision Medicine Initiative will pioneer a new model of patient-powered research that promises to accelerate biomedical discoveries and provide clinicians with new tools, knowledge, and therapies to select which treatments will work best for which patients.
June 30, 2015 - Advance for Laboratory - To accomplish all of this research, the precision medicine movement has, in turn, created an increased demand for human biospecimens - and, in particular, well-annotated biospecimens (i.e., biospecimens coupled with detailed specimen- and patient-level data). Well-annotated human biospecimens are biological "snapshots" of a patient during a specific moment in time and the cornerstone of effective translational research. Amazingly, at a time when we are studying disease at the genomic level, researchers still rely upon long-standing, frozen biospecimen inventories that often have very little patient data associated with them and therefore do not meet research needs. As personalized medicine develops and the role of the biospecimen becomes even more prominent, an emerging role for hospitals and labs becomes starkly apparent. The way we currently collect, store and annotate human biospecimens will have to change - a new model is needed.
June 30, 2015 - Health IT Analytics - When it comes to medical research and the rapidly expanding reach of precision medicine, physical specimens play a critical role in developing the big data later used for large-scale analytics that generate insights and produce results. Hospitals and clinics collect enormous amounts of blood, tissue, and other materials on a daily basis to use for diagnostic testing, but the remains of these samples don’t always make it into the hands of researchers and academics looking to further clinical trials and other projects. At Aurora Health Care, a fifteen-hospital chain based in Wisconsin, the Biorepository and Specimen Resource Center (BSRC) based at Aurora St. Luke’s Medical Center is helping to solve this problem by ensuring that patient specimens can be appropriately and securely used by researchers within the health system and across the country.
June 17, 2015 - G2 Intelligence - Technology is making use of hospital and laboratory specimens that would otherwise be discarded by connecting those specimen sources with biomedical researchers. iSpecimen (Lexington, Mass.), founded in 2009, links researchers with specimens from participating health care organizations and announced a new technology this month that uses its cloud-based platform, de-identified electronic medical record data and big data analytics to customize and increase the speed of that process.
Lexington, Mass – June 1, 2015 – iSpecimen, a trusted source of customized human biosp ecimen collections, is pleased to announce the appointment of Doug Williams to the position of Chief Technology Officer (CTO). Williams will be responsible for leading the team that builds out iSpecimen’s state-of-the-art, cloud-based platform that matches biomedical researchers with high quality, richly-annotated human biospecimens that would otherwise be discarded by hospitals and labs after clinical testing is complete.
May 17, 2015 - Advance for Laboratory - iSpecimen, a source of customized human biospecimen collections, has released its latest technology that connects biomedical researchers to high quality, annotated human biospecimens that would otherwise be discarded by hospitals and labs after clinical testing is complete. Through this model, researchers gain access to the specimens they need from the patients they want and healthcare providers gain a new opportunity to contribute to biomedical research while improving their bottom line.
Lexington, Mass – May 5, 2015 – iSpecimen, a trusted source of customized human biospecimen collections, today released its latest technology that connects biomedical researchers to high quality, annotated human biospecimens that would otherwise be discarded by hospitals and labs after clinical testing is complete. Through this model, researchers gain access to the specimens they need from the patients they want and healthcare providers gain a new opportunity to contribute to biomedical research while improving their bottom line.
June 3, 2014 -- iSpecimen announced today it has secured $8 million in capital in its Series B Financing. New investor OneBlood™, Inc., through a wholly owned subsidiary, in conjunction with existing investors, will help grow iSpecimen’s healthcare partner network and scale operations to meet the ever increasing needs of its research customers for annotated human biospecimens.
May 2014 -- iSpecimen announced the formation of the iSpecimen Partner Program. This turnkey program includes technology to automate the selection, annotation and management of laboratory discards; access to iSpecimen’s sales and marketing channel; compliance support; and laboratory SOPs to facilitate the disposition of clinical waste into medical research.
Jan. 2014 -- iSpecimen announced the deployment of the industry’s first federated specimen management system that greatly accelerates the pace at which scientists can obtain biospecimens for their research. The company’s Specimen Management System enables iSpecimen to deliver human biospecimens to the academic, diagnostic and pharmaceutical research community faster and with more consistent quality than traditional manual selection processes. The company also announced the availability of clinical specimen remnants – such as plasma, serum and urine – using this pioneering technology.
Jul. 2012-- iSpecimen announced today the closing of a $2.0M seed financing round. Led by private investors, the investment will be used to complete the development of the first version of its proprietary technology, which watches the flow of specimens in its network of clinical laboratories to match them to medical researchers’ customized specimen requests.
May 2012 -- iSpecimen has been selected as a finalist in the MassChallenge, an accelerator and startup competition. Finalists in the competition are provided mentorship, networking opportunities, free office space, and the chance to compete for $1M in funding at the end of the three month program.
At innovative companies such as iSpecimen, previously-used human clinical specimens are prospectively supplied “on demand” to the research, therapeutic and diagnostic industries. Such specimens include plasma, serum, whole blood, urine, CSF and tissue that are provided according to the needs of the customers’ study requirements. iSpecimen tracks millions of specimens, and the associated patient data that flows through its clinical partner network—which includes hospitals, commercial laboratories, specialty clinics and academic institutions. From them, the company is able to obtain remnant samples and de-identified patient data to help advance medical research, with partnership agreements that benefit both parties. Though the specimens are anonymized, demographic and clinical indicators such as specimen type, age, gender, ICD9 codes and test results are provided with the specimens for research optimization. According to Christopher Ianelli, M.D., Ph.D., founder and CEO of iSpecimen, “In today’s world of personalized medicine, researchers struggle to procure biospecimens from trusted sources. Often, they have to cobble together specimens and data from dozens of sources just to find enough specimens for their studies. The combination of iSpecimen’s pioneering Specimen Management System along with our robust network of clinical laboratory partners provides researchers with a steady supply of high-quality, annotated biospecimens.” Since a recent National Institutes of Health (NIH) article highlighted the increased interest in translational research and the concomitant need for researchers to be able to collect relevant and useful samples for their research, it would seem that iSpecimen is definitely onto something big.
- The New MOOD That Could Transform Healthcare: Massive Open Online Data
By Sue Montgomery, RN, BSN on Thursday 1st of May 2014
Mass HighTech News
Boston Business Journal